| CXSL2300638 | 注射用重组人凝血因子Ⅷ-Fc融合蛋白 | Recombinant Human Coagulation Factor VIII-Fc Fusion Protein | Lyophilized | Biological Products(2.4) | New Drug Application | 2023-09-21 | | Chengdu Rongsheng Pharmaceuticals Co Ltd | | | view |
| JYSB2100027 | 注射用重组人凝血因子VIII | Recombinant Coagulation Factor Ⅷ | Lyophilized | Biological Products | Supplementary Application | 2021-01-22 | | Pfizer Europe Ma Eeig;Wyeth Farma SA | In Review | 2021-01-21 | view |
| JYSB1500175 | 注射用重组人凝血因子VIII | Recombinant Coagulation Factor Ⅷ | Lyophilized | Biological Products | Supplementary Application | 2015-07-06 | | Wyeth Farma SA;Wyeth Pharmaceuticals Inc | Certificate Issued | 2015-12-25 | view |
| CXSS2200013 | 注射用重组人凝血因子Ⅷ | Recombinant Coagulation Factor Ⅷ | Lyophilized | Biological Products(3.4) | New Drug Application | 2022-02-07 | | Nanjing Shunxin Pharmaceuticals Co LTDof Chiatai Tianqing Pharmaceutical Group | | | view |
| JYSZ2100537 | 注射用重组人凝血因子Ⅷ | Recombinant Coagulation Factor Ⅷ | Lyophilized | Biological Products | License Renew | 2021-12-17 | | Baxalta Manufacturing Sàrl;Takeda Manufacturing Austria AG;Takeda (China) International Trading Co Ltd | | | view |
| JYSB1800188 | 注射用重组人凝血因子Ⅷ | Recombinant Coagulation Factor Ⅷ | Lyophilized | Biological Products | Supplementary Application | 2018-09-10 | | Wyeth Farma SA;Pfizer Ltd | Certificate Issued | 2019-02-02 | view |
| JXSS1000008 | 注射用重组人凝血因子VIII | Recombinant Coagulation Factor Ⅷ | Lyophilized | Biological Products | Import Drug Application | 2010-09-15 | | Wyeth Farma SA;Wyeth Pharmaceuticals Inc | Certificate Issued | 2012-08-28 | view |
| JYSB2200095 | 注射用重组人凝血因子VIII | Recombinant Coagulation Factor Ⅷ | Lyophilized | Biological Products | Supplementary Application | 2022-06-09 | | Pfizer Europe Ma Eeig;Wyeth Farma SA | | | view |
| JYSB1800047 | 注射用重组人凝血因子Ⅷ | Recombinant Coagulation Factor Ⅷ | Lyophilized | Biological Products | Supplementary Application | 2018-03-26 | | Bayer Healthcare LLC | Certificate Issued | 2018-07-27 | view |
| JYSB1700199 | 注射用重组人凝血因子Ⅷ | Recombinant Coagulation Factor Ⅷ | Lyophilized | Biological Products | Supplementary Application | 2017-11-22 | | Bayer Healthcare LLC | Certificate Issued | 2018-01-22 | view |
| JXSL0900046 | 注射用重组人凝血因子VIII | Recombinant Coagulation Factor Ⅷ | Lyophilized | Biological Products | Import Drug Application | 2009-07-01 | | Bayer Healthcare LLC | Certificate Issued | 2011-01-19 | view |
| CXSB2400122 | 注射用重组人凝血因子Ⅷ-Fc融合蛋白 | Recombinant Human Coagulation Factor VIII-Fc Fusion Protein | Lyophilized | Biological Products(2.4) | Supplementary Application | 2024-10-13 | | Chengdu Rongsheng Pharmaceuticals Co Ltd | | | view |
| JYSB2101028 | 注射用重组人凝血因子Ⅷ | Recombinant Coagulation Factor Ⅷ | Lyophilized | Biological Products | Supplementary Application | 2021-05-12 | | Bayer Healthcare LLC | | | view |
| JYSB2400050 | 注射用重组人凝血因子VIII | Recombinant Coagulation Factor Ⅷ | Lyophilized | Biological Products | Supplementary Application | 2024-03-07 | | Baxalta Manufacturing Sàrl;Takeda Manufacturing Austria AG | | | view |
| JYSB1900244 | 注射用重组人凝血因子VIII | Recombinant Coagulation Factor Ⅷ | Lyophilized | Biological Products | Supplementary Application | 2019-09-05 | | Wyeth Farma SA;Pfizer Ltd | Filed | 2019-09-16 | view |
| JYSB2200065 | 注射用重组人凝血因子Ⅷ | Recombinant Coagulation Factor Ⅷ | Lyophilized | Biological Products | Supplementary Application | 2022-04-08 | | Novo Nordisk A/S | | | view |
| JYSZ1600012 | 注射用重组人凝血因子Ⅷ | Recombinant Coagulation Factor Ⅷ | Lyophilized | Biological Products | License Renew | 2016-05-10 | | Baxter AG;Baxalta Manufacturing Sàrl | Certificate Issued | 2017-04-19 | view |
| CXSL2200294 | 注射用重组人凝血因子Ⅷ | Recombinant Coagulation Factor Ⅷ | Lyophilized | Biological Products(2.4) | New Drug Application | 2022-06-28 | | Zhuangya (Beijing) Biotechnology Co Ltd | | | view |
| CYSB2200145 | 人凝血因子Ⅷ | Recombinant Coagulation Factor Ⅷ | Lyophilized | Biological Products | Supplementary Application | 2022-06-08 | | Shanghai RAAS Blood Products Co Ltd | | | view |
| JYSB2000559 | 注射用重组人凝血因子VIII | Recombinant Coagulation Factor Ⅷ | Lyophilized | Biological Products | Supplementary Application | 2020-11-04 | | Bayer Healthcare LLC | Filed | 2020-11-17 | view |
